vTv Therapeutics Inc. (VTVT) Form 10-Q — May 13, 2026
vTv Therapeutics Inc. reported a significant revenue of $36.8 million for the three months ended March 31, 2026, primarily from a $20.0 million upfront fee received from Newsoara Biopharma Co., Ltd. and the recognition of $16.9 million in license revenue from G42. This marks a substantial improvement from the prior year, where no revenue was reported.
Key figures
- Eps
- 1.94
- Revenue
- 36839
- Net Income
- 24134
- Total Debt
- 8854
- Cash Position
- 98086
- Shares Outstanding
- 3938654
- License revenue g42
- 16900
- Upfront fee newsoara
- 20000
Price after filing
1 day: +21.4%7 days: +15.6%30 days: -0.2%
Close on the filing date to close N calendar days later (from $31.66). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.